



PolyNovo Limited
ABN 96 083 866 862

2/320 Lorimer Street
Port Melbourne
VIC Australia 3207

P +61 (0) 3 8681 4050
F +61 (0) 3 8681 4099

21 September 2021

ASX Announcement

First patient enrolled in Pivotal Trial - BARDA

PolyNovo is pleased to announce that the first patient has been enrolled in the pivotal arm of the BARDA funded burn study. The trial is being conducted in 20 US and 5 Canadian burn centres comprising up to 150 full thickness burn patients in a comparative study against the existing standard of care. It is estimated to take ~3 years, recruitment rate dependant. The study has BARDA funding support of \$15m USD.

Managing Director, Paul Brennan said, *"This is an exciting milestone in a trial that when concluded will generate data to support a premarket approval application with the US FDA for an on-label claim supporting the use of NovoSorb BTM in full thickness burns. This will bring our US market in line with global markets where this claim is already established."*

This announcement has been authorised by PolyNovo Company Secretary Jan-Marcel Gielen.

Further information:

Paul Brennan
Managing Director
Mobile: + 61 427 662 317

About NovoSorb®

NovoSorb® is a novel range of bio-resorbable polymers that can be produced in many formats including, film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and programmable bio-resorption profile. NovoSorb® BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery or burn.